fampridine   Click here for help

GtoPdb Ligand ID: 2416

Synonyms: 4-aminopyridine | 4-AP | Ampyra® | EL-970
Approved drug
fampridine is an approved drug (FDA (2010), EMA (2011))
Compound class: Synthetic organic
Comment: Fampridine is the INN for this compound, whereas its USAN is dalfampridine.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

fampridine is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 38.91
Molecular weight 94.05
XLogP -0.05
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Nc1ccncc1
Isomeric SMILES Nc1ccncc1
InChI InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)
InChI Key NUKYPUAOHBNCPY-UHFFFAOYSA-N
References
1. Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S, Brown AM. (1993)
Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.
Circ Res, 73 (1): 210-6. [PMID:8508531]
2. Finol-Urdaneta RK, Strüver N, Terlau H. (2006)
Molecular and Functional Differences between Heart mKv1.7 Channel Isoforms.
J Gen Physiol, 128 (1): 133-45. [PMID:16801386]
3. Gordon E, Cohen JL, Engel R, Abbott GW. (2006)
1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers.
Mol Pharmacol, 69 (3): 718-26. [PMID:16317109]
4. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG. (1994)
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Mol Pharmacol, 45 (6): 1227-34. [PMID:7517498]
5. Holmqvist MH, Cao J, Hernandez-Pineda R, Jacobson MD, Carroll KI, Sung MA, Betty M, Ge P, Gilbride KJ, Brown ME et al.. (2002)
Elimination of fast inactivation in Kv4 A-type potassium channels by an auxiliary subunit domain.
Proc Natl Acad Sci USA, 99 (2): 1035-40. [PMID:11805342]
6. Isbrandt D, Leicher T, Waldschütz R, Zhu X, Luhmann U, Michel U, Sauter K, Pongs O. (2000)
Gene structures and expression profiles of three human KCND (Kv4) potassium channels mediating A-type currents I(TO) and I(SA).
Genomics, 64 (2): 144-54. [PMID:10729221]
7. Juvin V, Penna A, Chemin J, Lin YL, Rassendren FA. (2007)
Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate.
Mol Pharmacol, 72 (5): 1258-68. [PMID:17673572]
8. Kalman K, Nguyen A, Tseng-Crank J, Dukes ID, Chandy G, Hustad CM, Copeland NG, Jenkins NA, Mohrenweiser H, Brandriff B et al.. (1998)
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
J Biol Chem, 273 (10): 5851-7. [PMID:9488722]
9. Kirsch GE, Drewe JA. (1993)
Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels.
J Gen Physiol, 102 (5): 797-816. [PMID:8301258]
10. Korenke AR, Rivey MP, Allington DR. (2008)
Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Ann Pharmacother, 42 (10): 1458-65. [PMID:18780812]
11. Krapivinsky G, Medina I, Eng L, Krapivinsky L, Yang Y, Clapham DE. (1998)
A novel inward rectifier K+ channel with unique pore properties.
Neuron, 20 (5): 995-1005. [PMID:9620703]
12. Lang R, Lee G, Liu W, Tian S, Rafi H, Orias M, Segal AS, Desir GV. (2000)
KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels.
Am J Physiol Renal Physiol, 278 (6): F1013-21. [PMID:10836990]
13. Lien CC, Martina M, Schultz JH, Ehmke H, Jonas P. (2002)
Gating, modulation and subunit composition of voltage-gated K(+) channels in dendritic inhibitory interneurones of rat hippocampus.
J Physiol (Lond.), 538 (Pt 2): 405-19. [PMID:11790809]
14. Schmalz F, Kinsella J, Koh SD, Vogalis F, Schneider A, Flynn ER, Kenyon JL, Horowitz B. (1998)
Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles.
Am J Physiol, 274 (5 Pt 1): G901-11. [PMID:9612272]
15. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. (2001)
Aminopyridines for symptomatic treatment in multiple sclerosis.
Cochrane Database Syst Rev, (4): CD001330. [PMID:11687106]
16. Stühmer W, Ruppersberg JP, Schröter KH, Sakmann B, Stocker M, Giese KP, Perschke A, Baumann A, Pongs O. (1989)
Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain.
EMBO J, 8 (11): 3235-44. [PMID:2555158]
17. Vega-Saenz de Miera E, Moreno H, Fruhling D, Kentros C, Rudy B. (1992)
Cloning of ShIII (Shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel.
Proc Biol Sci, 248 (1321): 9-18. [PMID:1381835]
18. Yeung SY, Ohya S, Sergeant GP, Pucovský V, Greenwood IA. (2006)
Pharmacological and molecular evidence for the involvement of Kv4.3 in ultra-fast activating K+ currents in murine portal vein myocytes.
Br J Pharmacol, 149 (6): 676-86. [PMID:17016508]